Our client, Alnylam Pharmaceuticals submits a sNDA to the FDA

Nov 4

Written By Kimberly Hicks

Kimberly Hicks

Exciting news! Our client, Dewpoint Therapeutics, has been recognized as “One to Watch” by The Pharma Letter.

We’re thrilled to celebrate our client, Pathos, as they expand their pipeline.